Mersana Therapeutics, Inc. has entered into a collaboration with Millennium Pharmaceuticals, a subsidiary of Takeda Pharmaceutical Co., to develop next-generation Fleximer antibody-drug conjugates (ADCs) using Mersana’s conjugation technology.   Mersana will receive an upfront payment for the right to use its Fleximer technology and is eligible to receive milestones and royalties on sales of any resulting ADC products. Mersana will be responsible for conducting research and creating ADCs that ar...